About:
Aptah Bio is a biotechnology company focused on developing innovative therapies for age-related diseases. Their proprietary technology platform, RNA WiCo™ (RNA Widespread Correction), allows them to edit, modulate, and control the expression of various ribonucleic acids (RNAs) in a unique way. By targeting and rejuvenating RNA molecules, Aptah Bio aims to address the underlying biological mechanisms contributing to age-related diseases. Their lead compound, APT20TTMG, is a synthetic cDNA single-stranded molecule designed to restore mRNA quality and ensure the proper synthesis of multiple proteins. This novel compound works by facilitating accurate U1 snRNP assembly, a critical step in RNA processing. By modulating RNA processing, APT20TTMG has the potential to address a wide range of sporadic genetic disorders. Aptah Bio's RNA WiCo™ technology and their lead compound, APT20TTMG, represent a promising approach to treating genetic diseases by targeting the fundamental mechanisms of RNA biology.
News: